Maria L Amador

Publications (2)6.42 Total impact

• Article: Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy.

  Eva Barragán, Pau Montesinos, Mireia Camos, Marcos González, Maria J Calasanz, José Román-Gómez, Maria T Gómez-Casares, Rosa Ayala, Javier López, Óscar Fuster, Dolors Colomer, Carmen Chillón, María J Larrayoz, Pedro Sánchez-Godoy, José González-Campos, Félix Manso, Maria L Amador, Edo Vellenga, Bob Lowenberg, Miguel A Sanz
  [show abstract] [hide abstract]
  ABSTRACT: Fms-like tyrosine kinase-3 (FLT3) gene mutations are frequent in acute promyelocytic leukemia but their prognostic value is not well established. We evaluated FLT3-internal tandem duplication and FLT3-D835 mutations in patients treated with all-trans retinoic acid and anthracycline-based chemotherapy enrolled in two subsequent trials of the Programa de Estudio y Tratamiento de las Hemopatías Malignas (PETHEMA) and Hemato-Oncologie voor Volwassenen Nederland (HOVON) groups between 1996 and 2005. FLT3-internal tandem duplication and FLT3-D835 mutation status was available for 306 (41%) and 213 (29%) patients, respectively. Sixty-eight (22%) and 20 (9%) patients had internal tandem duplication and D835 mutations, respectively. Internal tandem duplication was correlated with higher white blood cell and blast counts, lactate dehydrogenase, relapse-risk score, fever, hemorrhage, coagulopathy, BCR3 isoform, M3 variant subtype, and expression of CD2, CD34, human leukocyte antigen-DR, and CD11b surface antigens. The FLT3-D835 mutation was not significantly associated with any clinical or biological characteristic. Univariate analysis showed higher relapse and lower survival rates in patients with a FLT3-internal tandem duplication, while no impact was observed in relation to FLT3-D835. The prognostic value of the FLT3-internal tandem duplication was not retained in the multivariate analysis. FLT3-internal tandem duplication mutations are associated with several hematologic features in acute promyelocytic leukemia, in particular with high white blood cell counts, but we were unable to demonstrate an independent prognostic value in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens.
  Haematologica 06/2011; 96(10):1470-7. · 6.42 Impact Factor
• Source

  Available from: Mireia Camós

  Article: Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy

  Eva Barragan, Pau Montesinos, Mireia Camos, Marcos Gonzalez, Maria J Calasanz, Jose Roman-Gomez, Maria T Gomez-Casares, Rosa Ayala, Javier Lopez, Oscar Fuster, [......], Maria L Amador, Edo Vellenga, Bob Lowenberg, Miguel A Sanz, Calasanz Mj, Roman - Gomez, Gomez-Casares Mt, Larrayoz Mj, Amador Ml, Sanz Ma Prognostic
  [show abstract] [hide abstract]
  ABSTRACT: value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy. Haematologica. 2011; 96:xxx doi:10.3324/haematol.2011.044933 Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors' final approval; the final version of the manuscript will then appear in print on a regular issue of the journal. All legal disclaimers that apply to the journal also pertain to this production process.